Previous close | 275.40 |
Open | 275.00 |
Bid | 273.60 x 0 |
Ask | 0.00 x 0 |
Day's range | 273.00 - 275.80 |
52-week range | 229.80 - 298.40 |
Volume | |
Avg. volume | 2,592 |
Market cap | 201.415B |
Beta (5Y monthly) | 0.16 |
PE ratio (TTM) | 19.15 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 9.60 (3.49%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Roche (RHHBY) obtains approval for the subcutaneous formulation of relapsing multiple sclerosis drug Ocrevus in Europe. In addition, a review of the company's MAA for gene therapy, Elevidys, is also underway.
Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.
Roche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory diffuse large B-cell lymphoma in the phase III STARGLO study.